EA200802358A1 - Композиция для инактивации оболочечного вируса (варианты), способ лечения вирусного заболевания с ее помощью, средства на ее основе для изготовления лекарства против вирусного заболевания, для изготовления больших количеств биосовместимого дезинфецирующего средства и для изготовления покрытия, содержащий ее набор для инактивации оболочечного вируса и способ инактивации оболочечного вируса - Google Patents

Композиция для инактивации оболочечного вируса (варианты), способ лечения вирусного заболевания с ее помощью, средства на ее основе для изготовления лекарства против вирусного заболевания, для изготовления больших количеств биосовместимого дезинфецирующего средства и для изготовления покрытия, содержащий ее набор для инактивации оболочечного вируса и способ инактивации оболочечного вируса

Info

Publication number
EA200802358A1
EA200802358A1 EA200802358A EA200802358A EA200802358A1 EA 200802358 A1 EA200802358 A1 EA 200802358A1 EA 200802358 A EA200802358 A EA 200802358A EA 200802358 A EA200802358 A EA 200802358A EA 200802358 A1 EA200802358 A1 EA 200802358A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inactivation
virus
viral diseases
manufacturing
enveloped
Prior art date
Application number
EA200802358A
Other languages
English (en)
Other versions
EA016073B1 (ru
Inventor
Тьери Пеле
Доналд Ф.Х. Уалах
Original Assignee
Вайэроблок С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вайэроблок С.А. filed Critical Вайэроблок С.А.
Publication of EA200802358A1 publication Critical patent/EA200802358A1/ru
Publication of EA016073B1 publication Critical patent/EA016073B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation
    • C12N2760/18863—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Настоящее изобретение преимущественно относится к области предотвращения заболеваний, вызываемых оболочечными вирусами. Более конкретно, данное изобретение касается композиции для инактивации оболочечного вируса, содержащей по меньшей мере одну нефосфолипидную липосому (НФЛ), способную взаимодействовать с упомянутым оболочечным вирусом и с агентом, который усиливает липидный обмен между упомянутой НФЛ и мембраной упомянутого оболочечного вируса.
EA200802358A 2006-05-19 2007-05-18 Композиция для инактивации оболочечного вируса (варианты), средства на ее основе для приготовления лекарства против вирусного заболевания, для приготовления больших количеств биосовместимого дезинфицирующего средства и для приготовления покрытия, содержащий ее набор для инактивации оболочечного вируса и способ инактивации оболочечного вируса EA016073B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80140006P 2006-05-19 2006-05-19
PCT/IB2007/001286 WO2007135523A2 (en) 2006-05-19 2007-05-18 A composition for inactivating an enveloped virus

Publications (2)

Publication Number Publication Date
EA200802358A1 true EA200802358A1 (ru) 2009-04-28
EA016073B1 EA016073B1 (ru) 2012-01-30

Family

ID=37499627

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802358A EA016073B1 (ru) 2006-05-19 2007-05-18 Композиция для инактивации оболочечного вируса (варианты), средства на ее основе для приготовления лекарства против вирусного заболевания, для приготовления больших количеств биосовместимого дезинфицирующего средства и для приготовления покрытия, содержащий ее набор для инактивации оболочечного вируса и способ инактивации оболочечного вируса

Country Status (14)

Country Link
US (2) US8889398B2 (ru)
EP (1) EP2023896B8 (ru)
JP (1) JP5259578B2 (ru)
KR (1) KR101352165B1 (ru)
CN (1) CN101448486B (ru)
AU (1) AU2007252967B2 (ru)
BR (1) BRPI0712074A2 (ru)
CA (1) CA2652362C (ru)
DK (1) DK2023896T3 (ru)
EA (1) EA016073B1 (ru)
ES (1) ES2590812T3 (ru)
HK (1) HK1131554A1 (ru)
IL (1) IL195317A (ru)
WO (1) WO2007135523A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138173A1 (en) * 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
US20110229544A1 (en) * 2008-11-26 2011-09-22 Viroblock S.A. Methods for Inhibiting Gram-Postive Bacteria Using Non-Phospholipid Lipid Vesicules
CN102068425A (zh) * 2011-02-12 2011-05-25 李春娟 改良的磷酸奥司他韦药物组合物
PT3471732T (pt) * 2016-06-16 2020-08-24 Combioxin Sa Lipossomas para o tratamento de infeções virais
MX2020004151A (es) * 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
WO2021191141A1 (en) * 2020-03-26 2021-09-30 Heiq Materials Ag Antiviral surface coating for metal and plastic surfaces
US20230227506A1 (en) 2020-06-18 2023-07-20 The University Of Bristol Fatty Acid Complexes Of Coronavirus Spike Protein And Their Use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474848A (en) * 1987-03-13 1995-12-12 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) * 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5628936A (en) * 1987-03-13 1997-05-13 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5219538A (en) * 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
US5147723A (en) 1987-07-28 1992-09-15 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5032457A (en) * 1988-03-03 1991-07-16 Micro Vesicular Systems, Inc. Paucilamellar lipid vesicles using charge-localized, single chain, nonphospholipid surfactants
US5013497A (en) 1988-03-03 1991-05-07 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US4895452A (en) * 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5104736A (en) * 1988-03-03 1992-04-14 Micro-Pak, Inc. Reinforced paucilamellar lipid vesicles
US5013951A (en) * 1988-08-19 1991-05-07 Stadnik Ivan P Multipolar rotor for electric machine with interpolar and polar magnets
US5260065A (en) 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
US5405615A (en) * 1991-09-17 1995-04-11 Micro Vesicular Systems, Inc. Sucrose distearate lipid vesicles
US5439967A (en) * 1991-09-17 1995-08-08 Micro Vesicular Systems, Inc. Propylene glycol stearate vesicles
US5643600A (en) * 1991-09-17 1997-07-01 Micro-Pak, Inc. Lipid vesicles containing avocado oil unsaponifiables
WO1994016061A1 (en) 1993-01-15 1994-07-21 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
AU680996B2 (en) * 1993-12-17 1997-08-14 Novavax, Inc. Method of transmitting a biologically active material to a cell
FR2714067B1 (fr) 1993-12-22 1996-01-12 Commissariat Energie Atomique Nouveaux dérivés de cyclodextrines, utilisables en particulier pour solubiliser des composés chimiques hydrophobes tels que des médicaments, et leur procédé de préparation.
ES2193200T3 (es) * 1994-09-27 2003-11-01 Univ Leiden Composicion acuosa libre de fosfolipidos y colesterol para la aplicacion topica sobre la piel.
US6194555B1 (en) * 1995-11-04 2001-02-27 Texas Tech University Health Sciences Center Compositions and methods for regulation of steroidogenesis
US5872230A (en) * 1995-11-04 1999-02-16 Texas Tech University Health Sciences Center Compositions and methods for regulation of steroidogenesis
US6903183B1 (en) * 1996-06-07 2005-06-07 Texas Tech University Health Services Center Compositions and methods for regulation of steroidogenesis
FR2792942B1 (fr) * 1999-04-29 2001-06-08 Commissariat Energie Atomique Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes
IL129734A0 (en) 1999-05-03 2000-02-29 Compugen Ltd Novel nucleic acid and amino acid sequences
AUPR178300A0 (en) * 2000-11-29 2000-12-21 Heart Research Institute Ltd., The Cyclodextrins and reversal of atherosclerosis
EP1304103B1 (en) * 2001-10-22 2008-12-31 Viroblock SA New non-phospholipid lipid vesicles (npLV) and their use in cosmetic, therapeutic and prophylactic applications
JP2004066112A (ja) * 2002-08-07 2004-03-04 Canon Inc 乾式ブラスト洗浄における被洗浄物の除電方法および装置
US20050015847A1 (en) * 2002-08-08 2005-01-27 Scheele George A. Compositions and methods for preventing infection

Also Published As

Publication number Publication date
JP5259578B2 (ja) 2013-08-07
WO2007135523A3 (en) 2008-06-26
IL195317A0 (en) 2009-08-03
CN101448486B (zh) 2012-10-31
US9526700B2 (en) 2016-12-27
JP2009537508A (ja) 2009-10-29
IL195317A (en) 2014-02-27
US20150065458A1 (en) 2015-03-05
WO2007135523A2 (en) 2007-11-29
EP2023896B1 (en) 2016-07-13
EA016073B1 (ru) 2012-01-30
HK1131554A1 (en) 2010-01-29
EP2023896A2 (en) 2009-02-18
DK2023896T3 (en) 2016-10-03
AU2007252967B2 (en) 2011-11-10
KR101352165B1 (ko) 2014-01-15
KR20090014178A (ko) 2009-02-06
CA2652362A1 (en) 2007-11-29
US8889398B2 (en) 2014-11-18
EP2023896B8 (en) 2016-09-14
CN101448486A (zh) 2009-06-03
AU2007252967A1 (en) 2007-11-29
CA2652362C (en) 2014-10-07
BRPI0712074A2 (pt) 2012-01-17
US20100137437A1 (en) 2010-06-03
ES2590812T3 (es) 2016-11-23

Similar Documents

Publication Publication Date Title
EA200802358A1 (ru) Композиция для инактивации оболочечного вируса (варианты), способ лечения вирусного заболевания с ее помощью, средства на ее основе для изготовления лекарства против вирусного заболевания, для изготовления больших количеств биосовместимого дезинфецирующего средства и для изготовления покрытия, содержащий ее набор для инактивации оболочечного вируса и способ инактивации оболочечного вируса
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
EA025278B9 (ru) Антивирусная композиция против заключенных или незаключенных в оболочку днк- или рнк-вирусов
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
EA200900288A1 (ru) Вакцина
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
NO20073849L (no) Indolderivater for behandling av virale infeksjoner
WO2007084435A3 (en) Methods for treating hepatitis c
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
WO2011000566A3 (en) Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
EP2452693A3 (en) Vaccines and methods to treat canine influenza
DK1644363T3 (da) Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
EA201100794A1 (ru) Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак
EA201170349A1 (ru) Модуляторы mif
NO20084749L (no) Organiske forbindelser og deres anvendelser
EA201000277A1 (ru) Соединения для лечения гепатита с
AR053613A1 (es) Combinacion de compuestos activos fungicidas
CY1112842T1 (el) Νεες χρησεις ενωσεων προρφυρινης
DK2261377T3 (da) Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membran-fusogene kappeproteiner
WO2009053325A3 (de) Stabile, synergistische mischungen
EP2078083A4 (en) NEW DOG INFLUENZA VIRUS AND VEGETABLE THEREFOR
GT200600127A (es) Producto de combinacion de o-desmetilvenlafaxina y bazedoxifeno y usos del mismo
EA201100255A1 (ru) 5-алкинилпиримидины

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU